DH26002 Genomics Company V01 180126

 If you are referring to the specific company, it is formally known as Genomics plc (often simply referred to by its domain, Genomics.com).

Founded in 2014 by four world-leading geneticists from the University of Oxford—including Professor Sir Peter Donnelly—it is a major force in the "Genomic Prevention" movement. While bit.bio (the company we discussed earlier) focuses on writing and programming cells, Genomics plc focuses on reading and analyzing massive genetic datasets to predict disease risk.

1. What Does the Company Do?

Genomics plc uses a massive database of linked genetic and health data to understand how tiny variations in DNA lead to disease. Their work follows two main tracks:

• Genomic Prevention: They use Polygenic Risk Scores (PRS) to identify people at high risk for common diseases (like heart disease, breast cancer, or Type 2 diabetes) long before symptoms appear. This allows doctors to intervene years earlier than standard tests would allow.

• Drug Discovery: They partner with pharmaceutical giants (such as Vertex Pharmaceuticals) to use human genetics to identify new drug targets. By looking at "experiments of nature"—people who naturally have mutations that protect them from certain diseases—they can design drugs that mimic those protective effects.

2. Key Technology: The "Genomic Engine"

The company’s core asset is its proprietary analytical platform.

• It links over 14 million genetic variants to thousands of measurements and health outcomes.

• It is one of the largest and most sophisticated platforms of its kind in the world, using machine learning to find "signals" in the noise of 3 billion letters of DNA.

3. Real-World Impact (2025–2026)

• NHS Collaboration: They have been heavily involved in pilot programs with the UK's National Health Service (NHS) to integrate genetic risk testing into routine cardiovascular check-ups.

• Our Future Health: They are a key partner in "Our Future Health," the UK's largest-ever health research program, providing the technology to generate risk scores for up to 5 million participants.

• Expansion: As of 2026, the company has expanded its footprint significantly in the United States, with offices in Research Triangle Park (North Carolina) to bring their "genomic prevention" tools to American healthcare systems.

4. Leadership & Status

• CEO: Professor Sir Peter Donnelly, a renowned statistician and geneticist.

• Funding: They recently closed a $44 million Series C round (late 2024/early 2025) to accelerate their commercial rollout in the US and UK.

• Headquarters: Oxford, UK, with additional hubs in London, Cambridge, and the US.